Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Ganzinelli M, Rulli E, Caiola E, Garassino MC, Broggini M, Copreni E, Piva S, Longo F, Labianca R, Bareggi C, Fabbri MA, Martelli O, Fagnani D, Locatelli MC, Bertolini A, Valmadre G, Pavese I, Calcagno A, Sarobba MG, Marabese M.
Ganzinelli M, et al. Among authors: piva s.
Sci Rep. 2015 Nov 17;5:16331. doi: 10.1038/srep16331.
Sci Rep. 2015.
PMID: 26573509
Free PMC article.
Clinical Trial.